Fenella Raymond

Fenella Raymond is the co-founder and Lab Operations Manager at Salish Bioscience. She is also a co-founder of Ripple Biosolutions, which launched in 2018 as a provider of cell-free DNA products for next-generation sequencing applications.

Fenella has nearly thirty years of experience in both research science and project management at several biotechnology companies in the Seattle area. She researched the binding of MHC class II peptides at Virginia Mason Research Center (now Benaroya Research Institute), then moved to ZymoGenetics (later acquired by Bristol Myers Squibb) where she joined a team responsible for identifying novel drug targets downstream of the bioinformatic analysis. While at ZymoGenetics, Fenella’s interests shifted to Program Management where, amongst other projects, she provided project management support to recombinant human Thrombin from preclinical to BLA approval and assumed a lead role in the transition of interferon-lambda-1 through research into the development. Following a career shift into the non-profit world, Fenella was involved in the establishment of the Malaria Clinical Trial Center at Seattle Biomedical Research Institute (now the Center for Infectious Disease Research). Fenella received a BS in Chemistry from the University of California, Santa Cruz, in 1985.